Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-376
Overview: While GLP-1 agents are center stage in the medical and lay press, drugs in the class of sodium-glucose cotransporter 2 inhibitors (SGLT2is) are also quite remarkable at improving a variety of health endpoints. This episode provides an overview of studies supporting the use of SGLT2is to improve patient outcomes.
Episode resource links:
DM/HF:  Age Ageing 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254
Kidney stones: JAMA Intern Med. 2024 Jan 29:e237660. doi: 10.1001/jamainternmed.2023.7660
Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato

New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376

A weekly Podcast series covering newsworthy topics in primary care medicine.

Science

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-379
Overview: Recent data has shown that colchicine can improve outcomes in patients with known coronary artery disease (CAD), with consideration of colchicine now recommended by the American Heart Association (AHA). Hear valuable insights into the potential benefits and limitations to refine your clinical approach to managing CAD.
Episode resource links:
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838-1847. 
Mohammadnia N, Los J, Opstal TSJ, et al. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial. Front Cardiovasc Med. 2023;10:1244529. Published 2023 Oct 6. 
Roubille F, Bouabdallaoui N, Kouz S, et al. Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes Care. Published online January 5, 2024. 
Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Richard Onorato

Colchicine: It’s Not Just for Gout Anymore - Frankly Speaking Ep 379

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-378
Overview: Effective treatments for dementia remain elusive. In this episode, we’re discussing dementia treatment developments gathered from recent publications, covering topics of drugs, exercise, and liver disease. Stay informed and equipped to offer the latest guidance to patients with dementia and their families.
Episode resource links:
Ann Fam Med 2024;22:50-58. https://doi.org/10.1370/afm.3050
JAMA Netw Open. 2024;7(1):e2353965. doi:10.1001/jamanetworkopen.2023.53965
Guest: Robert A. Baldor, MD, FAAFP Music Credit: Richard Onorato

Dementia News Roundup - Frankly Speaking Ep 378

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-377
Overview: Fluid in the middle ear, or otitis media with effusion (OME), is common in children with upper respiratory infections and typically resolves without treatment. Most guidelines do not recommend antibiotics for treatment; however, they are often prescribed, and the persistence of effusion can cause a significant impact on quality of life. Join us as we discuss recent review findings on antibiotics in OME treatment and the potential impact on your practice.
Episode resource links:
Mulvaney CA, Galbraith K, Webster KE, et al. Antibiotics for otitis media with effusion (OME) in children. Cochrane Database Syst Rev. 2023;10(10):CD015254. Published 2023 Oct 23. doi:10.1002/14651858.CD015254.pub2
Rosenfeld, R. M., Shin, J. J., Schwartz, S. R., Coggins, R., Gagnon, L., Hackell, J. M., Hoelting, D., Hunter, L. L., Kummer, A. W., Payne, S. C., Poe, D. S., Veling, M., Vila, P. M., Walsh, S. A., & Corrigan, M. D. (2016). Clinical Practice Guideline: Otitis Media with Effusion (Update). Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 154(1 Suppl), S1–S41. https://doi.org/10.1177/0194599815623467
Guest: Susan Feeney, DNP, FNP-BC, NP-C Music Credit: Richard Onorato

To Treat or Not to Treat: Do Antibiotics Make a Difference with OME? - Frankly Speaking Ep 377

Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-375
Overview: Listen in as we discuss trends seen in breast cancer incidence over recent decades. Despite a notable rise in its prevalence, we’ve witnessed a decline in mortality rates. This positive shift owes itself to improvements in medication and screening efforts. Explore with us the multifaceted factors shaping this evolving landscape of breast cancer diagnosis and treatment.
Episode resource links:
https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html
https://www.uspreventiveservicestaskforce.org/uspstf/
Caswell-Jin, J. L., Sun, L. P., Munoz, D., Lu, Y., Li, Y., Huang, H., ... & Plevritis, S. K. (2024). Analysis of Breast Cancer Mortality in the US—1975 to 2019. JAMA, 331(3), 233-241.
Xu, S., Murtagh, S., Han, Y., Wan, F., & Toriola, A. T. (2024). Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Network Open, 7(1), e2353331-e2353331.
Guest: Mariyan L. Montaque, DNP, FNP-BC Music Credit: Richard Onorato

New Benefits Give SGLT2 Inhibitors Their Turn to Shine - Frankly Speaking Ep 376

Download our free app to listen on your phone